iMSC Induction From Mesenchymal Stromal Cells for Homogeneous Expansion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for generating induced mesenchymal stromal cells (iMSCs) from induced pluripotent stem cells (iPSCs) face challenges such as heterogeneity and limited proliferative capacity, and there is a lack of systematic comparison of iMSCs derived from different cell sources, which affects their clinical applications.
Innovation Solution
A method involving culturing iPSCs in specific media with TGF beta and ALK inhibitors, followed by trypsinization and seeding on coated or non-coated tissue culture with growth factors, to generate iMSCs efficiently, particularly from bone marrow-derived MSCs, ensuring high CD44 expression and similar cytokine secretion profiles to primary MSCs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If primary MSCs are used for therapy, then immunomodulatory functions are maintained, but proliferative capacity is limited and heterogeneity increases
Solution Approach 1:
The patent applies preliminary action by pre-differentiating iPSCs into iMSCs under controlled conditions before therapeutic use. The differentiation protocol using specific growth factors (TGF-β1, bFGF, EGF) and inhibitors (SB431542, LDN-193189) is established in advance to generate homogeneous iMSCs with desired immunomodulatory properties, solving the limitation of primary MSCs' limited proliferative capacity while maintaining functional reliability
Solution Approach 2:
The patent employs parameter changes by systematically optimizing culture conditions including growth factor concentrations, inhibitor dosages, and passage timing to control iMSC differentiation and expansion. This allows generation of large numbers of homogeneous cells with consistent immunomodulatory functions, resolving the contradiction between productivity and reliability
2Productivity
If iPSCs are reprogrammed from fibroblasts, then reprogramming efficiency is high, but lineage differentiation propensity is influenced by cellular origin
Solution Approach 1:
The patent applies local quality by using bone marrow-derived MSCs as the starting material for reprogramming, which have specific lineage characteristics. The differentiation protocol is locally optimized with specific growth factors and inhibitors to guide iMSC differentiation toward desired lineages, ensuring stable composition and predictable differentiation outcomes while maintaining high reprogramming efficiency
3Object-affected harmful factors
If non-viral reprogramming methods are used, then tumorigenicity risk is reduced, but reprogramming efficiency is low
Solution Approach 1:
The patent uses Sendai virus as an intermediary for reprogramming, which is a non-integrating viral vector that does not insert into the host genome, thus minimizing tumorigenicity risk while achieving high reprogramming efficiency. The Sendai virus delivers reprogramming factors temporarily, allowing efficient iPSC generation without the safety concerns of integrating viruses, and without the low efficiency of non-viral methods
Data Source
AI summary
Provided are mesenchymal stromal cells as a reprogramming source for ipsc induction. In particular, Provided is a method for generating induced mesenchymal stromal cells (iMSCs), the iMSC generated by the method as well as the use thereof.